Pfizer Oral Drug, Tofacitinib, for Ulcerative Colitis Meets Key Endpoints in Phase 3 Studies

Pfizer Oral Drug, Tofacitinib, for Ulcerative Colitis Meets Key Endpoints in Phase 3 Studies
Pfizer, Inc., recently announced that its investigational oral drug tofacitinib has met primary and key secondary endpoints in two Phase 3 studies evaluating its efficacy and safety in inducing remission in adult patients with moderately to severely active ulcerative colitis (UC). The results were given in oral presentations at the recent 11th Congress of the European Crohn’s and Colitis Organisation (ECCO). The OCTAVE (Oral Clinical Trials for tofAcitinib in ulceratiVE colitis) global clinical development program includes three Phase 3 studies, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain. The program also includes a long-term extension trial, the OCTAVE Open. OCTAVE Induction
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *